BFRA:NSD-Biofrontera AG (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.28

Change

-0.63 (-7.07)%

Market Cap

USD 0.20B

Volume

0.07M

Average Target Price

USD 8.00 (-3.38%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.39 (-0.52%)

USD72.87B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+0.46 (+0.08%)

USD59.07B 21.90 16.92
SGEN Seattle Genetics, Inc

-2.11 (-1.17%)

USD31.48B N/A N/A
MRNA Moderna, Inc

-0.61 (-0.87%)

USD27.57B N/A N/A
RPRX Royalty Pharma plc

-1.39 (-3.31%)

USD25.49B 35.14 9.58
GMAB Genmab A/S

-0.13 (-0.34%)

USD25.19B 27.12 3.06
ALXN Alexion Pharmaceuticals, Inc

-1.98 (-1.74%)

USD24.92B 30.43 27.52
BGNE BeiGene, Ltd

-2.89 (-1.05%)

USD23.57B N/A N/A
IMMU Immunomedics, Inc

-0.12 (-0.14%)

USD19.77B N/A N/A
INCY Incyte Corporation

-1.40 (-1.61%)

USD18.98B 47.64 35.20

ETFs Containing BFRA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.92% 34% F 38% F
Dividend Return 0.03% 20% F N/A N/A
Total Return -19.90% 34% F 37% F
Trailing 12 Months  
Capital Gain -40.86% 21% F 19% F
Dividend Return 0.02% 17% F N/A N/A
Total Return -40.84% 21% F 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.47% N/A N/A N/A N/A
Dividend Return 0.00% N/A N/A N/A N/A
Total Return -10.47% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.39% N/A N/A N/A N/A
Risk Adjusted Return -42.93% N/A N/A N/A N/A
Market Capitalization 0.20B 40% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 140.93 8% F 9% F
Price/Book Ratio 35.49 3% F 3% F
Price / Cash Flow Ratio -6.04 51% F 75% C
EV/EBITDA 139.28 5% F 5% F
Management Effectiveness  
Return on Equity -146.86% 20% F 8% F
Return on Invested Capital -82.07% 34% F 11% F
Return on Assets -11.79% 83% B 25% F
Debt to Equity Ratio 222.10% 12% F 9% F
Technical Ratios  
Short Ratio 0.04 99% A+ 98% A+
Short Percent N/A N/A N/A N/A N/A
Beta 1.38 57% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.